AdvaMed Announces Formation of Medical Imaging Division

World’s largest medical imaging companies join world’s largest medtech association

WASHINGTON, D.C.,  – Today, AdvaMed, the Medtech Association, announced the establishment of a new Medical Imaging Technology division focused on advocating on behalf of large and small companies for the essential role of medical imaging technology, radiopharmaceuticals, contrast media, and focused ultrasound devices in our nation’s health care system. Leading medical imaging companies – such as Bayer, Fujifilm Sonosite, GE HealthCare, Hologic, Philips, and Siemens Healthineers – have formally established AdvaMed as the new home for advocacy on behalf of medical imaging companies, which previously sat within the Medical Imaging & Technology Alliance (MITA), a division of the  National Electrical Manufacturers Association (NEMA)

AdvaMed President and CEO Scott Whitaker said : “This new division is a big step forward not merely for the medical imaging sector, but for AdvaMed and the entire medtech industry. Never before have medical technologies been so connected and interdependent as they are today—and it’s really only the beginning. From traditional medical devices to digital health tech to AI and medical imaging, the opportunity to unify the industry and advance policy solutions for the health care system has never been better. No trade organization is better prepared than AdvaMed to represent the entire medtech industry and take on these advocacy challenges so that our members can continue focusing on what they do best—meeting the needs of the patients they serve. 

“Finally, the timing of Peter Arduini’s election as our new Chair couldn’t be better. His leadership of GE HealthCare, a global leader in medical imaging, pharmaceutical diagnostics and digital solutions, will provide strategic insight and direction to AdvaMed as we work to ensure an aligned and inclusive focus across companies in every sector of medtech.”

Peter J. Arduini, President and CEO of GE HealthCare and newly elected Chair of the AdvaMed Board of Directors, said of the new division : “We are in a new era in which providers and patients rely on medical imaging and digital solutions for critical insights across the entire care pathway from screening, diagnosis, monitoring, and therapy delivery, as well as research and discovery.  As Chair, I look forward to working alongside Scott and my colleagues from across the industry to establish AdvaMed’s new imaging division and ensure it is aligned and integrated to our overall goals of the med tech industry.”

Patrick Hope served as executive director of MITA since 2015 and will now serve as executive director of the new Medical Imaging Technology division at AdvaMed. Hope said : “The future is brighter than ever for the medical imaging companies we served at MITA. Our new home at AdvaMed makes perfect sense: For the first time, we will be surrounded by a team, infrastructure, and resources focused entirely on the patients our companies serve. We will be surrounded by and working directly with experts in medtech policy at the state, national, and global levels. I am 100 percent confident that our companies will see more value in our work together under the AdvaMed umbrella than ever before.

Imaging plays a critical role in our health care system, from diagnosis to treatment:  

  • In the U.S., a medical image is taken every 3 seconds
  • Imaging makes up approximately 80 percent of AI technology cleared by FDA

As is the case with AdvaMed’s Accel, Dx, and Digital Health Tech divisions, AdvaMed’s new Medical Imaging Technology division will be led by a Board of Directors comprised of executives from its imaging company members. The new division will be led within AdvaMed by Patrick Hope, former Executive Director of the Medical Imaging Technology Alliance (MITA). Mr. Hope and Peter Weems, who led MITA’s government affairs and policy strategy, as well as other staff, will round out the division’s staffing needs at AdvaMed going forward.

This division’s creation comes on the heels of  AdvaMed’s announcement last month that it had established a Digital Health division. The recent creation of these two divisions “further demonstrates that AdvaMed is well positioned to lead the entire medtech industry on the advocacy front,” Whitaker said.

In January, AdvaMed will unveil a refreshed version of its “ Medical Innovation Agenda for the 118 th  Congress ,” a list of policy and legislative priorities critical to patient care that will include a new set of priorities for the medical imaging sector.

By Sheran Brown May 1, 2025
Opinion: Georgia's Congressional delegation can lead the way on correcting 'pill penalty'  Maria Thacker Goethe President and CEO, Georgia Life Sciences: May 1, 2025 EPIC Act offers commonsense fix to 'pill penalty' problem
By Maria Thacker Goethe April 18, 2025
The Science & Community Impacts Mapping Project (SCIMaP) shows how proposed federal funding cuts lead to reduced economic activity and job losses nationwide.
By Sheran Brown April 10, 2025
Georgia Life Sciences Selects Fulton County Schools Innovation Academy Student as the 2025 Georgia BioGENEius Winner Sandy Springs & Rockmart Teens Take Top Honors in Statewide Science Competition Atlanta, GA (April 4, 2025) – Georgia Life Sciences today named Bhavya Alapati , a junior at Fulton County Schools Innovation Academy, as the winner of the 2025 Georgia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. Eleven students from across Georgia competed for this year’s title and cash prize. Bhavya’s project investigated a novel method of identifying strokes using a device she created called SpectroStroke, a small-scale spectrophotometer, to detect homocysteine, an amino acid product that is associated with stroke. Bhavya identified the ability of homocysteine to be detected using Ellman’s reagent, which reacts with the free sulfhydryl group on the molecule to produce a yellow color. Bhavya created a wearable patch that contains the Ellman’s reagent. Then, she designed the SpectroStroke to be able to detect the color change when the patch is exposed to elevated levels of homocysteine. Bhavya’s SpectroStroke can detect normal levels of homocysteine up to extremely high levels seen in those experiencing a stroke. The ability to detect a stroke earlier would reduce damage and long-term effects of the condition. A future iteration of the SpectroStroke would include real-time monitoring capabilities to help track changing homocysteine levels. "Supporting and celebrating outstanding research and innovation in biotechnology is vital for the future of science and medicine. The Georgia BioGENEius Challenge not only encourages the brightest young minds to explore their potential but also nurtures the next generation of leaders who will drive groundbreaking advancements in biotechnology,” said Georgia Life Sciences President and CEO Maria Thacker-Goethe. “By recognizing and empowering these students, we are helping to shape a future where innovation thrives and the possibilities for improving lives are endless. Well done, Bhavya!” Georgia Life Sciences also congratulates the Georgia BioGENEius runner-up, Shelby Kendrick , who is a senior at Paulding County High School in Dallas, GA. Shelby’s research investigated the ability of Aspergillus terreus, a fungus found in soil, to degrade pre-treated polypropylene plastic (PP). This fungus has been discovered to produce high concentrations of degrading enzymes and raises the moisture level of its substrate. Shelby isolated the fungus from soil samples and confirmed the species using PCR amplification and DNA barcoding. Samples of polypropylene were pre-treated with 75% ethanol and UV exposure, then placed in a liquid culture of A. terreus in Minimal Salt Medium (MSM) media, and the culture was incubated for 23 days. At the end of the trial period, PP samples were analyzed using Scanning Electron Microscopy. These samples showed changes in their surface layer, indicating evidence of biodegradation. Polypropylene plastic is found in household items such as plastic cups and is a known problem in the environment due to its inability to degrade. Shelby’s future research on the use of A. terreus for biodegradation includes optimizing degradation conditions and assessing methods of application in the environment. Judging the 2025 Georgia BioGENEius Challenge were Ralph L. Cordell, CDC, and Alex Harvey, ViaMune. Cash prizes were awarded to Bhavya and Shelby. # # # About Georgia Life Sciences Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at galifesciences.org.
MORE POSTS